Back to search results

Evaluating Propionate and Butyrate for Intestinal Health

This study is looking at how taking microencapsulated sodium propionate and microencapsulated sodium butyrate affects the gut health of healthy volunteers. Researchers want to see if it's practical to give these supplements to patients who will have a stem cell transplant in the future. Propionate and butyrate are natural substances made in your gut that may help improve your gut's protective barrier. This study will check if participants can take at least 75% of the prescribed dose each week. You may be able to join if you are a healthy adult between 18 and 75 years old and can understand English. The study is currently unclear on its recruitment status, but plans to enroll 12 participants.

Study design
This is an interventional study with 12 planned participants. It is not specified if it is randomized or blinded.
What's involved
You would take microencapsulated sodium propionate orally four times daily for one week, then both microencapsulated sodium propionate and microencapsulated sodium butyrate orally four times daily for another week. You will also have blood samples collected throughout the study.
Compensation
Not stated in the trial record.
Follow-up
After completing the study intervention, participants are followed up for 1 week.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07611370

Evaluating the Effects of Propionate and Butyrate Supplementation on the Intestinal Health of Healthy Volunteers

Not Yet Recruiting
PHASE1Ages 18–75InterventionalSupportive care
City of Hope Medical Center
~12 participants
Updated 2026-05-28 on ClinicalTrials.gov
What's tested:Biospecimen CollectionMicroencapsulated Sodium ButyrateMicroencapsulated Sodium Propionate

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Subjects' ability to take at least 75% of the specified dose on a weekly basis (feasibility)
Measured over During 2 week intervention period

Conditions

Graft Versus Host Disease
Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm

Explore related trials

Healthy Volunteers

NCT07611370

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • City of Hope Medical Center

    Duarte, Californiastudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Karamjeet S Sandhu · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

Karamjeet S. Sandhu
[email protected]
626-218-2405
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Documented informed consent of the participant and/or legally authorized representative
Age: ≥ 18 years and ≤ 75 years old
Ability to read and understand and willingness to sign a written informed consent
Ability to understand English to fill out required forms (e.g. Pill Diary and Symptom Diary)
Participants are not taking butyrate or propionate as supplement(s)
Those who are already taking butyrate or propionate as supplement(s) are allowed only if they are willing to stop the supplement(s) ≥ 7 days prior to baseline samples and for the duration of this study

Exclusion

History of migraines and chronic gastrointestinal diseases, such as inflammatory bowel disease or Crohn's disease
History of allergic reactions to compounds of similar chemical or biologic composition to study agent
Females only: Pregnant, breastfeeding, or planning to get pregnant
Antibiotic exposure within 2 weeks prior to day 1 of study

What this trial measures

  • Subjects' ability to take at least 75% of the specified dose on a weekly basis (feasibility)During 2 week intervention period

    Evaluated by assessment of subject's ability to take at least 75% of the specified dose on a weekly basis. Vomiting within an hour after taking a dose will be considered a missed dose. Participants who do not meet this criterion will be considered as feasibility failure.